Table 3.
Fold-change in cytokine/chemokine production by immune cells in response to syncytin small interfering RNA microvesicles (syncytin siRNA MV)
| Molecule | Fold change relative to non-targeting siRNA MV | |
|---|---|---|
| IL-2 | 0·9 (± 0·04) | ns |
| IL-4 | 1·0 (± 0·04) | ns |
| IL-6 | 0·5 (± 0·05) | * |
| IL-8 | 1·5 (± 0·38) | ns |
| IL-10 | 0·8 (± 0·04) | * |
| IL-12 | 0·8 (± 0·02) | ns |
| IL-17 | 0·7 (± 0·05) | ns |
| G-CSF | 0·6 (± 0·05) | * |
| GM-CSF | 0·9 (± 0·04) | ns |
| IFN-γ | 0·9 (± 0·08) | ns |
| MCP-1 | 0·9 (± 0·04) | ns |
| MIP-1α | 0·4 (± 0·01) | ** |
| MIP-1β | 0·8 (± 0·01) | * |
| RANTES | 1·4 (± 0·04) | * |
| TNF-α | 0·5 (± 0·01) | * |
| VEGF | 1·0 (± 0·03) | ns |
| GRO-α | 0·9 (± 0·01) | * |
Peripheral blood mononuclear cells were treated with 20 μg/ml isolated MV derived from BeWo cells transfected with non-targeting siRNA, or BeWo cells transfected with human endogenous retrovirus W (HERV-W) -specific siRNA. Following a 24-hr incubation, cell-free supernatants were pooled and assayed by multiplex analysis. Numbers represent fold change of cytokine/chemokine production after treatment with syncytin siRNA MV relative to the level produced after treatment with non-targeting siRNA MV. Standard errors of the means are presented in parenthesis. Analysis was performed by unpaired t-test before calculation of fold-change.
P < 0·05
P < 0·01. ns indicates no significant difference.
IL-2, interleukin-2; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon-γ; MCP-1, monocyte chemoattractant protein 1; MIP, macrophage inhibitory protein; RANTES, regulated on activation normal T-cell expressed and secreted; TNF-α, tumour necrosis factor alpha; VEGF, vascular endothelial growth factor; GRO-α, growth-related oncogene-α.